Pierre Sierocki

Pierre Sierocki

Auto-generated profile, based on publicly available information

Pierre Sierocki

Univ. Lille, Inserm, Institut Pasteur de Lille, U1177, Drugs and Molecules for Living Systems 3 rue du Pr Laguesse 59000 Lille France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
VCVirgyl Camberlein
Virgyl Camberlein
CFCharlotte Fléau
Charlotte Fléau
PSPierre Sierocki
Pierre Sierocki
LLLenong Li
Lenong Li
RGRonan Gealageas
Ronan Gealageas
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain
Endoplasmic reticulum aminopeptidase 2 (ERAP2) is a key enzyme involved in the trimming of antigenic peptides presented by Major Histocompatibility Complex class I. It is a target of growing interest for the treatment of autoimmune diseases and in cancer immunotherapy. However, the discovery of potent and selective ERAP2 inhibitors is highly challenging. Herein, we have used kinetic target‐guided synthesis (KTGS) to identify such inhibitors. Co‐crystallization experiments revealed the binding mode of three different inhibitors with increasing potency and selectivity over related enzymes. Selected analogues engage ERAP2 in cells and inhibit antigen presentation in a cellular context. 4 d (BDM88951) displays favorable in vitro ADME properties and in vivo exposure. In summary, KTGS allowed the discovery of the first nanomolar and selective highly promising ERAP2 inhibitors that pave the way of the exploration of the biological roles of this enzyme and provide lead compounds for drug discovery efforts.

9 March 2022 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
PSPierre Sierocki
Pierre Sierocki
KGKrystal Gaillard
Krystal Gaillard
RRRuben Arturo Arellano Reyes
Ruben Arturo Arellano Reyes
CDChloé Donnart
Chloé Donnart
ELEmilie Lambert
Emilie Lambert
Jacques LebretonJacques Lebreton
Jacques Lebreton
We report the synthesis of C-nucleosides with a quaternary carbon at the anomeric position tethered to a 4-substituted 1,2,3-triazole ring and a cyano group, which were developed as potential antiviral agents.

30 September 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
VFVasileios Fougiaxis
Vasileios Fougiaxis
VBValentina Barcherini
Valentina Barcherini
MPMilena M. Petrovic
Milena M. Petrovic
PSPierre Sierocki
Pierre Sierocki
SWSandrine Warenghem
Sandrine Warenghem
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain
Inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) by small-molecules is being eagerly investigated for the treatment of various autoimmune diseases and in the field of immuno-oncology after its active involvement in antigen presentation and processing. Currently, ERAP1 inhibitors are at different stages of clinical development, which highlights its significance as a promising drug target. In the present work, we describe the first-ever successful identification of several ERAP1 inhibitors derived from a fragment-based screening approach. We applied an enzymatic activity assay to a large library of ∼3000 fragment entries in order to retrieve 32 hits. After a multi-faceted selection process, we prioritized 3 chemotypes for SAR optimization and strategic modifications provided 2 series (2-thienylacetic acid and rhodanine scaffolds) with improved analogues at the low micromolar range of ERAP1 inhibition. We report also evidence of selectivity against homologous aminopeptidase IRAP, combined with complementary in silico docking studies to predict the binding mode and site of inhibition. Our compounds can be the starting point for future fragment growing and rational drug development, incorporating new chemical modalities.

19 August 2022 in Angewandte Chemie
Verified
Journal Article
Open access
VCVirgyl Camberlein
Virgyl Camberlein
CFCharlotte Fléau
Charlotte Fléau
PSPierre Sierocki
Pierre Sierocki
LLLenong Li
Lenong Li
RGRonan Gealageas
Ronan Gealageas
RDRebecca Deprez-Poulain
Rebecca Deprez-Poulain
Endoplasmic reticulum aminopeptidase 2 (ERAP2) is a key enzyme involved in the trimming of antigenic peptides presented by Major Histocompatibility Complex class I. It is a target of growing interest for the treatment of autoimmune diseases and in cancer immunotherapy. However, the discovery of potent and selective ERAP2 inhibitors is highly challenging. Herein, we have used kinetic target‐guided synthesis (KTGS) to identify such inhibitors. Co‐crystallization experiments revealed the binding mode of three different inhibitors with increasing potency and selectivity over related enzymes. Selected analogues engage ERAP2 in cells and inhibit antigen presentation in a cellular context. 4 d (BDM88951) displays favorable in vitro ADME properties and in vivo exposure. In summary, KTGS allowed the discovery of the first nanomolar and selective highly promising ERAP2 inhibitors that pave the way of the exploration of the biological roles of this enzyme and provide lead compounds for drug discovery efforts.